Phreesia Faces Securities Fraud Lawsuits
Analysis based on 195 articles · First reported Apr 14, 2026 · Last updated Jun 11, 2026
The multiple class action lawsuits against Phreesia for alleged securities fraud have negatively impacted Phreesia's stock price, which fell 26.56% after the announcement of reduced revenue projections. This event highlights the risks associated with companies making misleading statements and the potential for significant financial losses for investors.
Multiple law firms, including Pomerantz LLP, Bronstein, Gewirtz & Grossman, LLC, Rosen Law Firm, and The Schall Law Firm, have filed or announced class action lawsuits against Phreesia. These lawsuits allege that Phreesia and its officers engaged in securities fraud by making materially false and misleading statements and failing to disclose crucial information to investors. Specifically, Phreesia is accused of misrepresenting its long-term growth outlook and confidence in fiscal year 2027 projections, particularly regarding its Network Solutions segment and pharmaceutical marketing commitments. On March 30, 2026, Phreesia announced significantly reduced revenue growth projections for fiscal year 2027, attributing the shortfall to 'worsening visibility' and weaker pharmaceutical marketing. This news led to a substantial drop in Phreesia's stock price, falling $3.03 per share, or 26.56%, to $8.38 per share on March 31, 2026. Investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, are encouraged to join these class actions, with a lead plaintiff deadline of July 13, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard